Sugi Predict

Sugi Predict / Compounds / SCHEMBL15317880

SCHEMBL15317880

SCHEMBL15317880

O=C(/C=C/CN1CCCCC1)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1CO

nearest known ligand 0.78

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 19/20 0.78
▸ ERBB2 P04626 12/20 0.78
▸ ERBB4 Q15303 11/20 0.78
▸ JAK3 P52333 4/20 0.78
▸ GAK O14976 1/20 0.78
▸ RIPK2 O43353 1/20 0.78
▸ NR1I2 O75469 1/20 0.78
▸ LCK P06239 1/20 0.78
▸ ADORA3 P0DMS8 1/20 0.78
▸ CHRM1 P11229 1/20 0.78
▸ SRC P12931 1/20 0.78
▸ DRD2 P14416 1/20 0.78
▸ ADRA2C P18825 1/20 0.78
▸ SLC6A2 P23975 1/20 0.78
▸ MC3R P41968 1/20 0.78
▸ SLC6A3 Q01959 1/20 0.78
▸ PDE4D Q08499 1/20 0.78
▸ KCNH2 Q12809 1/20 0.78
▸ RIPK3 Q9Y572 1/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21698585 0.91 EGFR (0.81) EGFRERBB2ERBB4JAK3GAK
SCHEMBL30115345 0.90 EGFR (0.82) EGFRERBB2ERBB4JAK3GAK
SCHEMBL16206672 0.90 EGFR (0.82) EGFRERBB2ERBB4JAK3GAK
SCHEMBL25309 0.90 EGFR (0.82) EGFRERBB2ERBB4JAK3GAK
SCHEMBL19545613 0.89 EGFR (0.78) EGFRERBB2ERBB4JAK3GAK
SCHEMBL21761406 0.88 EGFR (0.77) EGFRERBB2ERBB4JAK3GAK
SCHEMBL33136 0.88 EGFR (1.00) EGFRERBB2ERBB4JAK3GAK
Dacomitinib Anhydrous SCHEMBL29354322 0.88 EGFR (1.00) EGFRERBB2ERBB4JAK3GAK
SCHEMBL25098 0.88 EGFR (1.00) EGFRERBB2ERBB4JAK3GAK
Dacomitinib Anhydrous SCHEMBL33147 0.88 EGFR (1.00) EGFRERBB2ERBB4JAK3GAK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230001008-A1 COMPOSITIONS AND METHODS FOR TARGETING CELLULAR MOLECULES KUMQUAT BIOSCIENCES INC. 2023-01-05 — — US disclosed
US-20160017431-A1 Methods for Predicting EGFR Tyrosine Kinase Inhibitor Efficacy DRIVER GROUP (US) 2016-01-21 — — US disclosed
US-8623883-B2 4-phenylamino-quinazolin-6-yl-amides WARNER-LAMBERT COMPANY LLC (US) 2014-01-07 — — US disclosed
US-20130274275-A1 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES WARNER-LAMBERT COMPANY LLC 2013-10-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230001008-A1 COMPOSITIONS AND METHODS FOR TARGETING CELLULAR MOLECULES CD2BP2, CD47, CD74 EGFR 1892/4885ERBB2 2230/4885ERBB4 2991/4885
US-20160017431-A1 Methods for Predicting EGFR Tyrosine Kinase Inhibitor Efficacy EGFR, ERBB2, ERBB3 EGFR 1/4885ERBB2 2/4885ERBB4 4/4885
US-20130274275-A1 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES HRH4, HRH3, HRH2 EGFR 1504/4885ERBB2 1415/4885ERBB4 1648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.